AroCell AB (Nasdaq First North Growth Market:AROC), a Swedish supplier of blood and urine sample tests, announced on Friday that it has received patent approval in China for its invention on detecting and classifying respiratory infections.
This follows earlier approvals from the European Patent Office in July 2024 and the Japanese Patent Office in September 2024.
The patent covers the use of serum thymidine kinase 1 (STK1) to diagnose Mycoplasma pneumonia and classify respiratory infections as bacterial, viral or caused by M. pneumoniae. Chinese approval strengthens AroCell's intellectual property portfolio across key global markets.
While AroCell primarily focuses on urology, the patent supports the potential clinical application of its TK 210 ELISA technology in respiratory infections. The company now has expanded opportunities for its diagnostic solutions in China, the EU and Japan.
OS Therapies secures US patent for OST-HER2 manufacturing, extending exclusivity to 2040
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
Kexing Biopharm's GB05 IND application receives US FDA approval
AroCell secures Chinese patent for respiratory infection detection
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Polarean Imaging expands reach with Taiwanese distribution deal
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma